$BRCNF

Burcon NutraScience (TSX: BU) announced shareholder meeting results, with all director nominees elected. Shareholders approved a $21M convertible debenture financing. The company updated its commercial guidance, expecting at least $6M in 2026 revenue and a $10M annualized run rate by year-end. Positive cash flow is anticipated in 2027. Investments in manufacturing infrastructure are being accelerated to meet growing customer demand.

Burcon NutraScience (TSX: BU) upsized its convertible debenture financing from $8.1M to $21M due to strong investor interest. The company postponed its AGSM to September 24, 2026, to allow shareholders to review updated materials. Proceeds will fund growth, efficiency, and debt repayment. The TSX conditionally approved the offering, subject to shareholder approval.

Stonegate Capital Partners updated coverage on Burcon Nutrascience Corporation (BU) after its 1Q27 results. The company reported revenue of $1.28M, up 54% quarter over quarter and 273% year over year, with active buying customers rising to 40. Stonegate noted a $1.76M inventory write-down and said execution depends on customer traction, Galesburg capacity expansion, and planned up to $8.1M financing to support a 2H ramp.

Burcon NutraScience (TSX: BU, OTCQB: BRCNF) reported fiscal 2027 Q1 results for the three months ended June 30, 2026. Revenue rose to C$1.3 million, up 54% sequentially and 273% year over year. Net loss was C$3.8 million (C$0.30/share). Cash was C$0.9 million with negative working capital. The company also announced a C$1.4 million related-party loan and a private placement of convertible debentures up to C$8.1 million.